Telemedicine for Children With Sickle Cell Disease

Sponsor
Indiana University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05087303
Collaborator
(none)
60
1
2
35.4
1.7

Study Details

Study Description

Brief Summary

The purpose of this study is to learn more about how the use of two different types of telemedicine (distance medical care) can address barriers to receiving comprehensive sickle cell care, and whether care can be improved. Aim 1: Adapt two telemedicine models (i.e., hub-and-spoke; direct-to-consumer) for use with children with SCD using caregiver input from our preliminary K12 work. Aim 2: Demonstrate the feasibility of the telemedicine models developed in Aim 1 as the models undergo successive stakeholder refinement during use in actual clinical care. Aim 3: Evaluate the effectiveness of the refined models from Aim 2 in a pre/post study by assessing (a) process of care measures, (b) provider satisfaction, (c) caregiver/patient-centered outcomes, and (d) clinical outcomes and healthcare utilization.

Condition or Disease Intervention/Treatment Phase
  • Other: Types of Telemedicine Delivery Models
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Telemedicine for Pediatric Sickle Cell Patients in Medically Underserved Areas
Actual Study Start Date :
Sep 21, 2021
Anticipated Primary Completion Date :
Sep 1, 2024
Anticipated Study Completion Date :
Sep 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Hub and Spoke

Other: Types of Telemedicine Delivery Models
Each arm delivers standard sickle cell care using a different model based on patient location.

Active Comparator: Direct to Consumer

Other: Types of Telemedicine Delivery Models
Each arm delivers standard sickle cell care using a different model based on patient location.

Outcome Measures

Primary Outcome Measures

  1. Measuring adherence to appointment in sickle cell care. [1 year]

    Failed appointments in Electronic Medical Record - no more than one failed appointment during pilot year.

  2. Measuring adherence to lab draws in sickle cell care. [6 months]

    Adherence to lab draws - a minimum of one complete blood count per six months.

  3. Measuring healthcare utilization pre and post telemedicine participation. [1 year]

    Will determine the frequency of 1) vasoocclusive pain episode; 2) acute chest syndrome; 3) Emergency department visits; 4) hospitalizations. This data will be collected through chart abstraction from Electronic Medical Record one year prior to study entry and one year on study.

  4. Measuring collaboration of primary care provider and subspecialty care provider. [1 year]

    Documentation of Primary Care Provider communication of visits in the electronic medical record at least 70% of the time.

  5. Provider Feedback [1 year]

    Telemedicine Acceptance Questionnaire (TAQ) - will be given to all providers participating in telemedicine visits after every telemedicine visit. 0-5 Likert scale

  6. Caregiver feedback [1 year]

    Telemedicine satisfaction survey (TESS) - administered to caregivers following each telemedicine visit. 0-5 Likert scale

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A to 21 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients must be between 0 to 21 years old with Sickle Cell Disease and receive care at the Riley Hospital for Children Comprehensive Sickle Cell Disease clinic.

  • The family must be willing to receive their care using the telemedicine model available to them based on the location of their primary residence.

  • TeleSCD model participants must live within 1 hour of the pre-identified telemedicine sites, while VirtualSCD model participants must live within the city limits of the pre-identified area.

Exclusion Criteria:
  • If a patient receives chronic transfusion therapy, they will not be eligible to participate, as our telemedicine models will not support this.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Indiana University Indianapolis Indiana United States 46202

Sponsors and Collaborators

  • Indiana University

Investigators

  • Principal Investigator: Seethal Jacob, MD, Indiana University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Seethal Jacob, MD, MS, Assistant Professor of Pediatrics, Indiana University
ClinicalTrials.gov Identifier:
NCT05087303
Other Study ID Numbers:
  • 2101344406
First Posted:
Oct 21, 2021
Last Update Posted:
Jul 29, 2022
Last Verified:
Jul 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 29, 2022